NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Cetuximab and panitumumab for previously untreated metastatic colorectal cancer - NICE TAG TA439

Cetuximab and panitumumab for previously untreated metastatic colorectal cancer - NICE TAG TA439

1.1 Cetuximab is recommended, within its marketing authorisation, as an option for previously untreated epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in adults in combination with:

  • 5‑fluorouracil, folinic acid and oxaliplatin (FOLFOX) or

  • 5‑fluorouracil, folinic acid and irinotecan (FOLFIRI).

1.2 Panitumumab is recommended, within its marketing authorisation, as an option for previously untreated RAS wild-type metastatic colorectal cancer in adults in combination with:

  • FOLFOX or

  • FOLFIRI.

1.3 The drugs are recommended only when the companies provide them with the discounts agreed in their patient access schemes.

https://www.nice.org.uk/guidance/ta439

Site by Devopa
© Copyright 2019 NHS. All rights reserved.